Triplet Therapeutics Layoffs

Recent News and Discussions About Triplet Therapeutics Layoffs

Triplet Therapeutics nabs Scholar Rock R&D exec as new CSO

https://www.fiercebiotech.com/biotech/triplet-therapeutics-nabs-scholar-rock-r-d-exec-as-new-cso

Triplet Therapeutics nabs Scholar Rock R&D exec as new CSO
Triplet Therapeutics nabs Scholar Rock R&D exec as new CSO … plans to narrow its R&D focus to cancer and pain, at the expense of up to 37 staff layoffs .


Triplet Therapeutics launches with $59M, Nessan …

https://www.fiercebiotech.com/biotech/triplet-therapeutics-launches-59m-nessan-bermingham-at-wheel

Dec 17, 2019 — Just two months after launching Korro Bio, he’s unveiling a new biotech, Triplet Therapeutics , with $59 million and a mission to develop drugs …


End-of-Year Restructuring Means Layoffs for These Companies

https://www.biospace.com/article/a-look-at-biopharma-layoffs/

Nov 16, 2021 — Based in South San Francisco, Rigel has 195 staffers and plans to cut 31 positions by the end of the year and take a fourth-quarter charge of …


These 4 startups got venture funding a year ago. Where are …

Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?

Jan 5, 2021 — Triplet Therapeutics and three other startups got venture funding a year ago. Did they achieve what they hoped to?


For some biotech employees in the age of COVID-19, the …

https://www.bostonglobe.com/2020/06/16/business/some-biotech-employees-age-covid-19-workday-starts-bathroom-sink/

Jun 16, 2020 — In Cambridge, Triplet Therapeutics , a biotech working on treatments for devastating rare genetic disorders, has turned to technology to keep …


Exelixis trots out triplet win in kidney cancer – Fierce Pharma

https://www.fiercepharma.com/pharma/exelixis-trot-out-opdivo-yervoy-cabometyx-combo-win-kidney-cancer-will-fda-accept

4 days ago — The company attributed layoffs to “economic challenges that are impacting … Paxlovid has surpassed other COVID therapeutics in the U.S., …


The top 10 drugs losing US exclusivity in 2022 | Fierce Pharma

https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2022

The first copycat came from Eagle Pharmaceuticals in February. … If it weren’t for COVID-19, Gilead Sciences’ HIV triplet Biktarvy would still be the …


Triplet Therapeutics Launches with $59 Million in Financing to …

https://www.businesswire.com/news/home/20191217005165/en/Triplet-Therapeutics-Launches-with-59-Million-in-Financing-to-Further-its-Development-of-Transformative-Treatments-for-Triplet-Repeat-Disorders

Dec 17, 2019 — Triplet Therapeutics launched today with $59 million in financing to target the common pathway involved in triplet repeat disorders.


Blueprint Medicines gets more ducks in a row before CEO …

Blueprint Medicines gets more ducks in a row before CEO transition; Paul Stoffels has his work cut out for him at Gilead’s crumbling partner

Feb 2, 2022 — Ho, a veteran of TCR2 Therapeutics and Agios Pharmaceuticals, … posts at Triplet Therapeutics and was Moderna’s senior corporate counsel, …


biotech layoffs 2020

http://surveys.afew.org.ua/web/assets/site/699d86-biotech-layoffs-2020

Triplet Therapeutics Prior to joining the cell therapy company, Hastings served as the director of ViaCyte, the lead independent director of Pacira …


Leave a Comment